Keyword Analysis & Research: encorafenib ema
Keyword Research: People who searched encorafenib ema also searched
Search Results related to encorafenib ema on Search Engine
-
Explore further
https://www.pierre-fabre.com/en/press_release/pierre-fabre-receives-european-approval-for-braftovir-encorafenib
WebThe active substance in Braftovi, encorafenib, works by blocking the BRAF protein thereby stopping its activation of cell division and slowing down the growth and spread of the …
DA: 60 PA: 63 MOZ Rank: 39
-
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf
WebAdministration of encorafenib should be undertaken with caution at a dose of 300 mg once daily in patients with mild hepatic impairment (Child-Pugh Class A). No dosing … File Size: 838KB Page Count: 53
File Size: 838KB
Page Count: 53
DA: 80 PA: 80 MOZ Rank: 82
-
Mektovi | European Medicines Agency
https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi
WebMektovi is a medicine for treating melanoma (a skin cancer) that has spread or cannot be removed by surgery. Mektovi is used in combination with another medicine, encorafenib …
DA: 58 PA: 76 MOZ Rank: 86
-
Prescribing information | Braftovi
https://www.braftovi-crc.com/prescribing-information
WebBRAFTOVI (encorafenib) is indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who …
DA: 59 PA: 64 MOZ Rank: 19
-
European Medicines Agency validates Pierre Fabre Laboratories
https://www.prnewswire.com/news-releases/european-medicines-agency-validates-pierre-fabre-laboratories-marketing-authorisation-application-for-combination-braftovi-encorafenib-and-mektovi-binimetinib-for-patients-with-brafv600-mutant-advanced-non-small-cell-lung-c-301975614.html
WebNov 2, 2023 · Pierre Fabre Laboratories announced today that the European Medicines Agency (EMA) validated the submission for BRAFTOVI ® (encorafenib) + MEKTOVI ® …
DA: 71 PA: 23 MOZ Rank: 17
-
EMA Recommends Extension of Indications for Encorafenib
https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-encorafenib
WebMay 6, 2020 · EMA Recommends Extension of Indications for Encorafenib. It is indicated in combination with cetuximab for the treatment of adult patients with metastatic colorectal …
DA: 59 PA: 19 MOZ Rank: 78
-
The EMA assessment of encorafenib in combination with
https://www.sciencedirect.com/science/article/pii/S2059702920328969
WebFeb 1, 2021 · The recommended dose of encorafenib is 300 mg (four 75-mg capsules) once daily, when used in combination with cetuximab. This was added to the prior …
DA: 86 PA: 58 MOZ Rank: 95
-
The EMA assessment of encorafenib in combination with
https://pubmed.ncbi.nlm.nih.gov/33422765/
Web10.1016/j.esmoop.2020.100031. On 2 June 2020, a marketing authorisation valid through the European Union (EU) was issued for encorafenib in combination with cetuximab in …
DA: 55 PA: 23 MOZ Rank: 2
-
The EMA assessment of encorafenib in combination with …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809377/
WebJan 8, 2021 · Encorafenib is a selective ATP-competitive RAF kinase inhibitor that suppresses the RAF/MEK/ERK pathway in tumour cells expressing several mutated …
DA: 94 PA: 10 MOZ Rank: 71
-
Pierre Fabre receives European approval for BRAFTOVI® …
https://www.pierre-fabre.com/en/press_release/pierre-fabre-receives-european-approval-for-braftovir-encorafenib
WebPierre Fabre today announced that the European Commission (EC) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as Erbitux®) for …
DA: 20 PA: 89 MOZ Rank: 48